Hydronephrosis Treatment Market Growth, Share and Forecast 2034
Global Hydronephrosis Treatment Market Growth, Size, Trends Analysis- By Type, By Indication, By Diagnosis, By Treatment, By Age Group - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jul-2025 | Report ID: HLCA25209 | Pages: 1 - 250 | Formats*: |
| Category : Healthcare | |||
Global Hydronephrosis Treatment Market Introduction and Overview
According to SPER Market Research, the Global Hydronephrosis Treatment Market is estimated to reach USD 5.86 billion by 2034 with a CAGR of 8.46%.
The report includes an in-depth analysis of the Global Hydronephrosis Treatment Market, including market size and trends, product mix, Applications, and supplier analysis. The rising prevalence of kidney diseases, including chronic kidney disease (CKD), is a key factor driving market growth. Hydronephrosis treatment involves medical procedures to address kidney swelling caused by urinary tract blockages. Increased use of advanced imaging techniques like MRI and CT scans is enhancing diagnostic accuracy and supporting market expansion. CKD, influenced by factors such as diabetes, hypertension, and obesity, affects approximately 35.5 million U.S. adults, significantly contributing to the progression of end-stage renal disease (ESRD). However, Challenges in the hydronephrosis treatment market include high costs of advanced diagnostic tools and limited access to specialized care in low-resource settings. Additionally, delayed diagnosis and lack of awareness can hinder timely treatment and patient outcomes.
By Type:
The hydronephrosis treatment market is segmented into unilateral and bilateral types, with unilateral hydronephrosis holding a dominant revenue share. This segment's growth is driven by structural abnormalities in the urinary tract, such as ureteropelvic junction obstructions and ureteral strictures, which commonly cause unilateral kidney swelling. Additionally, differences in healthcare provider practices—including diagnostic methods, treatment strategies, and follow-up care—can influence the demand for treatment. These factors collectively contribute to the rising focus on managing unilateral hydronephrosis effectively.
By Indications:
The hydronephrosis treatment market is divided into intrinsic and extrinsic indications, with the intrinsic segment leading in revenue. This growth is driven by conditions like kidney stones, urinary tract infections, benign prostatic hyperplasia, pelvic tumors, and congenital abnormalities, which commonly cause hydronephrosis. Increasing sedentary lifestyles, poor diets, and higher consumption of processed foods contribute to the rising prevalence of these conditions. Consequently, lifestyle factors significantly influence the incidence of hydronephrosis-related diseases, fueling market expansion.
By Treatment:
The hydronephrosis treatment market is segmented into shock wave lithotripsy (SWL), laparoscopy, bladder catheterization, steroid therapy, and other treatments, with SWL leading in revenue and expected to grow significantly. Compared to surgical options like ureteroscopy or percutaneous nephrolithotomy, SWL offers less discomfort and quicker recovery, allowing patients to resume normal activities sooner. The rising global incidence of kidney stones, driven by factors like diet, dehydration, obesity, and metabolic disorders, is increasing demand for effective treatments such as SWL.
By Diagnosis:
The hydronephrosis treatment market is divided into laboratory tests and imaging, with imaging holding the largest revenue share. Imaging methods are generally non-invasive, making them the preferred choice for diagnosing hydronephrosis, particularly in pediatric and elderly patients or those with comorbidities who face higher risks from invasive procedures. Additionally, patients often favor imaging techniques for their comfort and convenience, which further boosts demand for these diagnostic tools in managing hydronephrosis.
By Age Group:
The hydronephrosis treatment market is categorized by age group into adult and pediatric segments, with the pediatric segment holding a significant share. Many pediatric cases are congenital, caused by structural abnormalities or urinary tract malformations present at birth, driving growth in this segment. Additionally, advancements in prenatal imaging and widespread prenatal screening enable early detection of hydronephrosis during pregnancy, allowing timely intervention and treatment planning, which further boosts demand for pediatric treatment options.
Regional Insights:
The North American hydronephrosis treatment market is experiencing substantial growth due to its well-developed healthcare infrastructure, including advanced hospitals, specialized clinics, and cutting-edge diagnostic and treatment technologies. Access to these resources improves the diagnosis and management of hydronephrosis, boosting treatment demand. Additionally, the region’s high prevalence of obesity and diabetes—key risk factors for kidney stones and urinary tract conditions—contributes to the rising incidence of hydronephrosis, further driving market expansion.
Market Competitive Landscape:
The global Hydronephrosis Treatment Market is highly consolidated. Some of the market key players are AbbVie Inc, Amgen Inc, The Anthem Group, F. Hoffmann-La Roche Ltd, Nephrogenex Inc., Novartis AG, Pfizer Inc., Phraxis Inc., Renal Associates P.A., and Sanofi.
Recent Developments:
In June 2023, Novartis AG strengthened its focus on innovative medicines and its renal pipeline by acquiring Chinook Therapeutics. This acquisition is expected to enhance the company’s drug portfolio for kidney disease treatment.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Type, By Indication, By Diagnosis, By Treatment, By Age Group |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | AbbVie Inc, Amgen Inc, The Anthem Group, F. Hoffmann-La Roche Ltd, Nephrogenex Inc., Novartis AG, Pfizer Inc., Phraxis Inc., Renal Associates P.A., and Sanofi. |
Key Topics Covered in the Report
- Global Hydronephrosis Treatment Market Size (FY’2021-FY’2034)
- Overview of Global Hydronephrosis Treatment Market
- Segmentation of Global Hydronephrosis Treatment Market By Type (Unilateral hydronephrosis, Bilateral hydronephrosis)
- Segmentation of Global Hydronephrosis Treatment Market By Indication (Intrinsic, Extrinsic)
- Segmentation of Global Hydronephrosis Treatment Market By Diagnosis (Laboratory Tests, Imaging)
- Segmentation of Global Hydronephrosis Treatment Market By Treatment (Shock wave lithotripsy, Laparoscopy, Bladder catheterization, Steroid therapy, Other treatment types)
- Segmentation of Global Hydronephrosis Treatment Market By Age Group (Adult, Pediatric)
- Statistical Snap of Global Hydronephrosis Treatment Market
- Expansion Analysis of Global Hydronephrosis Treatment Market
- Problems and Obstacles in Global Hydronephrosis Treatment Market
- Competitive Landscape in the Global Hydronephrosis Treatment Market
- Details on Current Investment in Global Hydronephrosis Treatment Market
- Competitive Analysis of Global Hydronephrosis Treatment Market
- Prominent Players in the Global Hydronephrosis Treatment Market
- SWOT Analysis of Global Hydronephrosis Treatment Market
- Global Hydronephrosis Treatment Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape
5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Hydronephrosis Treatment Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Hydronephrosis Treatment Market
7.Global Hydronephrosis Treatment Market, By Type, (USD Million) 2021-2034
7.1.Unilateral hydronephrosis7.2.Bilateral hydronephrosis
8.Global Hydronephrosis Treatment Market, By Indication, (USD Million) 2021-2034
8.1.Intrinsic
8.1.1.Acute unilateral obstructive uropathy8.1.2.Kidney stone8.1.3.Bladder cancer8.1.4.Bladder stones8.1.5.Urethral stricture8.1.6.Pelvic organ prolapse8.1.7. Other intrinsic indications
8.2.Extrinsic
8.2.1.Retroperitoneal fibrosis8.2.2.Ovarian vein syndrome8.2.3.Other extrinsic indications
9.Global Hydronephrosis Treatment Market, By Diagnosis, (USD Million) 2021-2034
9.1.Laboratory tests
9.1.1.Urinalysis9.1.2.Complete blood count9.1.3.Electrolyte analysis9.1.4.Other laboratory tests
9.2.Imaging
9.2.1.Ultrasound9.2.2.Intravenous pyelography9.2.3.KUB X-Rays9.2.4.CT-scan9.2.5.Other imaging types
10.Global Hydronephrosis Treatment Market, By Treatment, (USD Million) 2021-2034
10.1.Shock wave lithotripsy10.2.Laparoscopy10.3.Bladder catheterization10.4.Steroid therapy10.5.Other treatment types
11.Global Hydronephrosis Treatment Market, By Age Group, (USD Million) 2021-2034
11.1.Adult11.2.Pediatric
12.Global Hydronephrosis Treatment Market, (USD Million) 2021-2034
12.1.Global Hydronephrosis Treatment Market Size and Market Share
13.Global Hydronephrosis Treatment Market, By Region, 2021-2034 (USD Million)
13.1.Asia-Pacific
13.1.1.Australia13.1.2.China13.1.3.India13.1.4.Japan13.1.5.South Korea13.1.6.Rest of Asia-Pacific
13.2.Europe
13.2.1.France13.2.2.Germany13.2.3.Italy13.2.4.Spain13.2.5.United Kingdom13.2.6.Rest of Europe
13.3.Middle East and Africa
13.3.1.Kingdom of Saudi Arabia13.3.2.United Arab Emirates13.3.3.Qatar13.3.4.South Africa13.3.5.Egypt13.3.6.Morocco13.3.7.Nigeria13.3.8.Rest of Middle-East and Africa
13.4.North America
13.4.1.Canada13.4.2.Mexico13.4.3.United States
13.5.Latin America
13.5.1.Argentina13.5.2.Brazil13.5.3.Rest of Latin America
14.Company Profile
14.1.AbbVie Inc
14.1.1.Company details14.1.2.Financial outlook14.1.3.Product summary14.1.4.Recent developments
14.2.Amgen Inc
14.2.1.Company details14.2.2.Financial outlook14.2.3.Product summary14.2.4.Recent developments
14.3.The Anthem Group
14.3.1.Company details14.3.2.Financial outlook14.3.3.Product summary14.3.4.Recent developments
14.4.F. Hoffmann-La Roche Ltd
14.4.1.Company details14.4.2.Financial outlook14.4.3.Product summary14.4.4.Recent developments
14.5.Nephrogenex Inc.
14.5.1.Company details14.5.2.Financial outlook14.5.3.Product summary14.5.4.Recent developments
14.6.Novartis AG
14.6.1.Company details14.6.2.Financial outlook14.6.3.Product summary14.6.4.Recent developments
14.7.Pfizer Inc.
14.7.1.Company details14.7.2.Financial outlook14.7.3.Product summary14.7.4.Recent developments
14.8.Phraxis Inc.
14.8.1.Company details14.8.2.Financial outlook14.8.3.Product summary14.8.4.Recent developments
14.9.Renal Associates P.A.
14.9.1.Company details14.9.2.Financial outlook14.9.3.Product summary14.9.4.Recent developments
14.10.Sanofi
14.10.1.Company details14.10.2.Financial outlook14.10.3.Product summary14.10.4.Recent developments
14.11.Others
15.Conclusion
16.List of Abbreviations
17.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
The report includes an in-depth analysis of the Global Hydronephrosis Treatment Market, including market size and trends, product mix, Applications, and supplier analysis.
Hydronephrosis Treatment Market is projected to reach USD 5.86 billion by 2034, growing at a CAGR of of 8.46% during the forecast period.
Hydronephrosis Treatment Market grew in Market size from 2025. The Market is expected to reach USD 5.86 billion by 2034, at a CAGR of 8.46% during the forecast period.
Hydronephrosis Treatment Market CAGR of 8.46% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Hydronephrosis Treatment Market size is USD 5.86 billion from 2025 to 2034.
Hydronephrosis Treatment Market is covered By Type, By Indication, By Diagnosis, By Treatment, By Age Group
The North America is anticipated to have the highest Market share in the Hydronephrosis Treatment Market.
AbbVie Inc, Amgen Inc, The Anthem Group, F. Hoffmann-La Roche Ltd, Nephrogenex Inc., Novartis AG, Pfizer Inc., Phraxis Inc., Renal Associates P.A., and Sanofi.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
